Hepatocyte growth factor (HGF) overexpression is an important mechanism in acquired epidermal growth factor receptor (EGFR) kinase inhibitor gefitinib resis- 
miR-1, 6 miR-34b/c, 7 miR-449a, 8 and so on. miRNA-1 (mainly refer to miR-1-3p) and miR-206 are members of the muscle-specific miR-1 family of so-called myomiRs, 9 which play an important role in the myogenesis and development of cardiac and skeletal muscles. 10, 11 A multitude of recent studies showed that deregulation of myomiR expression is associated with a variety of cancers. [12] [13] [14] [15] In lung cancer, miR-1 and miR-206 have been found exhibited antitumour activities in multiple aspects, including repression of cell proliferation, migration, invasion and angiogenesis. For example, Korde et al 12 found that miR-1 levels were lower in NSCLC than cancerfree tissue and overexpression of miR-1 could reduce tumour growth and angiogenesis by targeting Mpl gene. Chiu et al 16 showed that ADAM9 down-regulated miR-1 expression, which in turn enhanced CDCP1 expression to promote lung cancer progression. Singh et al 17 reported that down-regulation of miRÀ1/À206
in NSCLC has major effects on carbon flux and the activity of metabolic pathways associated with cell proliferation and growth.
Furthermore, we and other researchers have found that low expression of miR-206 is related to lung cancer invasion and metastasis. 18, 19 However, the role of miR-1-3p and miR-206 in HGFinduced gefitinib resistance of lung cancer is not clear.
This study was performed to investigate whether miR-1-3p and miR-206 increased the sensitivity of HGF-induced gefitinib resistance in EGFR mutant lung cancer cells. We assessed this issue using human lung cancer cells, PC9 and HCC-827, both harbouring deletions in exon19 of EGFR. The results showed that HGF-induced gefitinib resistance and miR-1-3p and miR-206 could circumvent the HGF-induced gefitinib resistance by targeting c-Met-Akt-Erk pathway and suppressing epithelial-mesenchymal transition (EMT).
| MATERIALS AND METHODS

| Cell cultures
The EGFR mutant (exon 19 deletion) human lung adenocarcinoma cell lines, PC-9, were provided by Affiliated Hangzhou Hospital of Nanjing Medical University. HCC827 cell line was purchased from the Cell Bank at the Chinese Academy of Sciences. Both the cell lines were maintained in RPMI 1640 medium supplemented with 10% FBS and antibiotics.
| miRNA transfection
The miRNA mimics or negative control mimics were chemically synthesized by GenePharma Co., Ltd. (shanghai, China), and the transfection was conducted as we described previously. 20 All miRNA sequences are listed in Table S1 . Transfection efficiency was confirmed by SYBR green (Takara) real-time PCR detection of miR-1-3p
and miR-206 expression.
| c-Met knockdown and overexpression
For knockdown of c-Met, c-Met shRNA expression vector (PGPU6/ GFP/neo-shRNA-c-Met, designated as sh-Met) and the control vector PGPU6/GFP/neo-shControl (designated as sh-NC) were provided by GenePharma Inc (Shanghai, China). c-Met shRNA sequences are listed in Table S2 . 
| HGF overexpression
Hepatocyte growth factor overexpression lentivirus (Leti-Ubi-MCS-3FLAG-SV40-puromycin-HGF) was constructed by GeneCHEM inc (Shanghai, China). PC-9 and HCC827 cells were infected in accordance with the manufacturer's instructions. After puromycin selection, HGF-producing cell lines, PC-9/HGF and HCC827/HGF, were established. HGF production in these cells was determined by ELISA method.
| Cell viability assay
The cell viability was detected by MTT method. Tumour cells (4 9 10 3 per well) were plated into 96-well plates and allowed to adhere overnight. Then, the cells were transfected with miRNA mimics or mimic NC. After 24 hours of incubation, different concentrations of gefitinib (0.001-1 lmol/L) and/or HGF were added, and incubation was continued for 48-72 hours. The cell survival rate was determined with MTT solution (5 mg/mL; Sigma). Each sample was plated in quintuplicate, and three independent experiments were performed.
| Migration and invasion assay
Wound healing experiment and transwell assays were used to determine the migration and invasion abilities of the cells, respectively.
The experiments were conducted as we described previously. | 3527 internal control. The primers for miR-1-3p and miR-206 were in Table S3 .
| Western blot analysis
Cells were harvested and lysed on ice for 30 minutes in RIPA buffer (Beyotime) supplemented with protease inhibitor cocktail (Roche).
Lysates were subjected to Western blotting assay as described previously 21 and detected with antibodies against p-Met, c-Met, p-EGFR, EGFR, phospho-AKT, total AKT, phospho-ERK, total ERK, GAPDH, E-cadherin, Vimentin and Snail (Cell signalling technology). plates. Luciferase assays were performed 24 hours after transfection using the Dual-Luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity.
| Immunofluorescence staining
| Animal studies
All experimental procedures involving animals in this study had been approved by the ethics committee in the 117th Hospital of PLA.
Male nude mice (BALB/c, 4 weeks old) were purchased from Shang- 
| Statistical analysis
All data were presented as the means AE standard deviation. Differences between samples were analysed using two-tailed Student's t test. P < .05 was considered statistically significant. miR-1-3p and miR-206 have been identified as tumour suppressors in various human cancers, including lung cancer. 6, 12, 17, 18, 23, 24 Exogenous expression of these two miRNAs could significantly reduce cell motility and invasiveness. 25 In this study, we evaluated Among them, miR-1-3p and miR-206, which belong to muscle-specific miRNAs and play key roles in skeletal muscle differentiation, have found exhibited inhibitory function in lung cancer growth, migration and invasion in recent years. [16] [17] [18] However, other functions of these two miRNAs are not known. In this study, we Epithelial-mesenchymal transition is another mechanism of acquired EGFR-TKI resistance in lung cancers. In vitro studies showed that the mesenchymal phenotype is more resistant to EGF-TKI than the epithelial phenotype. 45 Activated HGF/c-Met pathway drives a mesenchymal phenotype in liver cancer has been reported. 46 In our study, both morphologic observation and molec- 
